calcitonin has been researched along with Granuloma--Giant-Cell* in 5 studies
1 review(s) available for calcitonin and Granuloma--Giant-Cell
Article | Year |
---|---|
Central giant cell granuloma of the jaws: a clinical study of 17 cases and a review of the literature.
The aim of this prospective study was to evaluate the outcome of treatment of a group of 17 patients with central giant cell granuloma (CGCG) who were treated in our clinic.. A group of 17 patients with CGCG were treated in the Clinic of Oral and Maxillofacial Surgery of the "G. Papanikolaou" hospital in Thessaloniki. The age range was from 7 to 60 years. Eight patients were male and 9 patients were female. Because most of our patients (11) were less than 30 years old, the aim of the treatment was to eradicate the lesions without functional problems. All of the patients were treated by excision via curettage without a continuity defect and peripheral osteotomy. For 2 patients, the treatment was continued (after the first recurrence) with salmon calcitonin.. The follow-ups ranged from 1 to 15 years. All of the patients were free of the disease, without features of recurrence and without functional or aesthetic problems.. Surgery has usually been considered to be the best method of treatment for CGCG. Most authors have proposed conservative surgical procedures (excision via curettage), especially for young patients. For aggressive lesions, supplementary treatment with calcitonin would provide good results. Topics: Adolescent; Adult; Bone Density Conservation Agents; Calcitonin; Child; Curettage; Female; Follow-Up Studies; Granuloma, Giant Cell; Humans; Jaw Diseases; Male; Mandible; Maxilla; Middle Aged; Osteotomy; Young Adult | 2011 |
2 trial(s) available for calcitonin and Granuloma--Giant-Cell
Article | Year |
---|---|
Can calcitonin nasal spray reduce the risk of recurrence of central giant cell granuloma of the jaws? A double-blind clinical trial.
Recurrence is a major problem following the treatment of aggressive central giant cell granuloma (CGCG). The aim of this study was to compare the frequency of recurrence between patients who received calcitonin nasal spray after curettage of CGCGs and those who did not. A double-blind clinical trial was designed. Patients were allocated to one of two groups: those in the calcitonin group underwent curettage and received calcitonin salmon nasal spray 200IU/day once a day for 3 months after surgery; those in the control group underwent curettage of CGCGs and received a placebo once a day for 3 months after surgery. All patients were followed for 5 years after surgery. Twenty-four patients were treated in the two groups. There was no difference in age, sex, tumour size, or tumour location between the two groups (P>0.05). Eight of the 24 patients (33.3%) had recurrences during the follow-up period: one in the calcitonin group (9.1%) and seven in the control group (53.8%). Analysis of the data demonstrated a significant difference between the two study groups (P=0.033). It appears that calcitonin nasal spray may reduce the frequency of recurrence in aggressive CGCGs in the mandible and maxilla. Topics: Adolescent; Adult; Bone Density Conservation Agents; Calcitonin; Double-Blind Method; Female; Granuloma, Giant Cell; Humans; Male; Mandibular Diseases; Maxillary Diseases; Nasal Sprays; Recurrence; Secondary Prevention | 2016 |
Calcitonin therapy in central giant cell granuloma of the jaw: a randomized double-blind placebo-controlled study.
The successful therapeutic use of calcitonin in patients with a central giant cell granuloma has been shown in several case reports. In a prospective, randomized, double-blinded, placebo-controlled clinical trial, 14 patients with a histologically confirmed central giant cell granuloma and normal calcium and parathyroid hormone serum levels were studied over 2 years. Patients were treated with intranasally administered salmon calcitonin (200 IU/day) or a placebo once a day. The placebo-controlled period was 3 months, after which all patients were treated with calcitonin for 1 year. Treatment response was assessed at the end of the placebo-controlled study phase (3 months), at the end of therapy (15 months' timepoint with patients being on calcitonin treatment for either 12 or 15 months) and at 6 months' follow-up. The chi(2)-test was used to compare the proportion of patients with a tumour reduction >/=10% of the pretreatment measurement between the 2 populations at the 3 timepoints: no differences were observed between the placebo group and the calcitonin group. At the 6-month follow-up timepoint, tumour volume had decreased by >/=10% in a total of 7 patients with a 37.9% (95% CI 31.3-44.5%) mean volume reduction in this subgroup. Complete remission was not observed. Topics: Adolescent; Adult; Bone Density Conservation Agents; Calcitonin; Chi-Square Distribution; Child; Double-Blind Method; Female; Granuloma, Giant Cell; Humans; Jaw Diseases; Male; Middle Aged; Prospective Studies; Radiography | 2006 |
2 other study(ies) available for calcitonin and Granuloma--Giant-Cell
Article | Year |
---|---|
Calcitonin: a non-invasive giant cells therapy.
This paper reports four cases of central giant cell granuloma (CGCG) treated with calcitonin, attesting the efficacy and safety of its use as the chosen therapy for large CGCG. Four patients presenting CGCG treated with calcitonin were included in this study. Salmon calcitonin was administered for 6-28 months. It was observed determination of clear lesion limits for surgery, reduction and limitation of lesions. In aggressive cases, the calcitonin therapy was an excellent option, since it does not harm the patient, and a far less aggressive, complementary surgery may be performed in certain cases, avoiding life-long sequelae. Topics: Adolescent; Adult; Bone Density Conservation Agents; Calcitonin; Child; Female; Granuloma, Giant Cell; Humans; Jaw Diseases; Male; Radiography | 2008 |
Limited regression of central giant cell granuloma by interferon alpha after failed calcitonin therapy: a report of 2 cases.
Central giant cell granuloma (CGCG) is a benign lesion of the jaws with a sometimes locally aggressive behaviour. The most common therapy is surgical curettage which has a high recurrence rate, especially in lesions with aggressive signs and symptoms (i.e. pain, paresthesia, root-resorption and rapid growth). Alternative therapies such as interferon alpha (INFalpha) or calcitonin are described in the literature. In this study 2 patients with an aggressive CGCG are presented who were treated with INF mono-therapy. INF mono-therapy was capable of terminating the rapid growth of the lesion in both patients and induced a partial reduction. Total resolution, however, was not obtained and alternative treatment is still necessary. Topics: Adolescent; Adult; Bone Density Conservation Agents; Calcitonin; Female; Granuloma, Giant Cell; Humans; Interferon-alpha; Male; Mandible; Mandibular Diseases; Maxilla; Maxillary Diseases; Radiography; Remission Induction; Treatment Failure | 2006 |